Avamax Indications/Uses

Hyperlipidemia: Atorvastatin is indicated: As adjunct to diet to decrease elevated total-C, LDL-C, Apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson types IIa and IIb).
As adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable to decrease total-C and LDL-C in patients with homozygous familial hypercholesterolemia.
To increase HDL-C and decrease the LDL-C/HDL-C and total-C/HDL-C ratios.
As adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson type IV).
As adjunct to diet for the treatment of patients with dysbetalipoproteinemia (Fredrickson type III).
As adjunct to diet to decrease total-C, LDL-C, and Apo B levels in boys and postmenarchal girls 10 to 17 years old with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and: There is a positive family history of premature cardiovascular disease or two or more other cardiovascular risk factors are present in the patient.
Prevention of Cardiovascular Disease: In adult patients without clinical evidence of coronary heart disease (CHD), but with multiple risk factors for CHD (e.g., age, smoking, hypertension, low HDL-C, or a family history of early CHD), atorvastatin is indicated to: Decrease the risk of myocardial infarction (MI); Decrease the risk of stroke; Decrease the risk of revascularization procedures and angina.
In patients with type 2 diabetes without clinical evidence of CHD but with multiple risk factors for CHD (e.g., retinopathy, albuminuria, smoking, hypertension), atorvastatin is indicated to: Decrease the risk of MI; Decrease the risk of stroke.
In patients with clinical evidence of CHD, atorvastatin is indicated to: Decrease the risk of nonfatal MI; Decrease the risk of fatal and nonfatal stroke; Decrease the risk for revascularization procedures; Decrease the risk of hospitalization for congestive heart failure (CHF); Decrease the risk of angina.